Allterum Therapeutics is building an oncology franchise targeting the IL-7 axis starting with a monoclonal antibody against IL-7Rα.

Developing treatments for
IL-7R expressing
cancers.



INNOVATION
WHO WE ARE
Allterum Therapeutics, Inc., is a biopharmaceutical company targeting the IL-7 pathway for the treatment of IL-7R expressing cancers. Allterum was founded in 2018 by Fannin Innovation Studio in Houston, TX.
image
OUR FOCUS

Why Allterum Therapeutics

image

Relapsed/Refractory Hematologic Malignancies

Allterum is initially focusing on developing therapies for patients with relapsed disease who may not have effective standard options available to them. In particular, patients with relapsed/refractory T-cell ALL and B-cell hematologic malignancies, while relatively rare, have a relatively poor prognosis as a result of a lack of effective therapies.

image

Lymphomas and Solid Tumors with IL-7R Over-expression

Allterum is actively identifying other cancers with IL-7R over-expression where patients may benefit from treatment with our monoclonal antibody.

Our Partnerships & Collaborators

image

Allterum is a Fannin Innovation Studio company.

Fannin Innovation Studio is Houston's most active early-stage life sciences development group with the primary focus being on development of early stage assets, in partnership with our academic collaborators. The studio’s assests include internally developed assets like Brevitest and in-licensed assets from academic institutions including local Houstonian institutions such as MD Anderson Cancer Center, Baylor College of Medicine, Rice University, Houston Methodist, Texas A&M, Texas Children’s, University of Texas, and University of Houston.

ALLTERUM THERAPEUTICS

Advancing an innovative solution for a critical and unmet medical need